This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I42.3 (endomyocardial disease) | Special Copayment Reduction: V127 (rare disease) |
| B. Synonyms | Endomyocardial (eosinophilic) disease | Endomyocardial (tropical) fibrosis | Löffler endocarditis |
| C. Adult onset | Likelihood of first onset in adulthood: high — Löffler endocarditis (eosinophilic) mainly presents in adult middle age (30~60 years) and is often accompanied by hypereosinophilic syndrome. Tropical endomyocardial fibrosis also occurs in childhood and adolescence, but adult onset is common as well, and it is sometimes diagnosed especially in adult immigrants from tropical regions. |
| 1. History | 1936 Davies first described endomyocardial fibrosis in tropical Africa → 1936 Löffler reported eosinophilic endocarditis → 1968 continuity of the two diseases recognized. |
| 2. Causes | Eosinophilic: hypereosinophilic syndrome (parasites, allergy, hematologic malignancy). Tropical: multiple causes, including nutritional deficiency, genetic predisposition, and infection. |
| 3. Genetics | Mostly non-hereditary. Some HLA-associated predisposition reported in tropical endomyocardial fibrosis. FIP1L1-PDGFRA fusion gene in hypereosinophilic syndrome. |
| 4. General epidemiology | Tropical: a major cause among rare diseases in parts of Africa and South Asia. Eosinophilic: rare worldwide. Both extremely rare in Korea. |
| 5. Pathophysiology | Eosinophil degranulation → toxic injury to endocardium and myocardium → fibrosis → restrictive cardiomyopathy. |
| 6. Symptoms | Dyspnea, ascites, lower limb edema. Thromboembolism, symptoms due to mitral and tricuspid regurgitation. |
| 7. Signs | Elevated jugular venous pressure, ascites, heart murmur (atrioventricular valve regurgitation). ECG abnormalities; echocardiography shows endocardial thickening and restricted ventricular filling. |
| 8. Screening | Regular echocardiography and cardiac MRI to evaluate cardiac involvement in patients with hypereosinophilic syndrome. Differentiation in patients with fever of unknown origin or heart failure who have lived in or visited tropical regions. |
| 9. Diagnosis | Echocardiography (endocardial thickening, apical thrombus, atrioventricular valve regurgitation). Cardiac MRI (LGE). Endomyocardial biopsy. Peripheral blood eosinophil count. |
| 10. Treatment | Eosinophilic: corticosteroids, imatinib if FIP1L1-PDGFRA positive. Anticoagulation. Tropical: diuretics, anticoagulation, surgical endocardiectomy and valve surgery. |
| 11. Prognosis | Improvement possible with early treatment. Poor at the advanced fibrotic stage (end stage). 5-year survival about 70~80% after surgical endocardiectomy. |
| 12. Prevention | Prevention of cardiac involvement by treating the cause of hypereosinophilic syndrome. Nutritional supplementation and treatment of parasites in tropical regions. Anticoagulation to prevent thrombosis. |
| 13. References | Mocumbi AO, et al. Endomyocardial fibrosis. Cardiovasc Diagn Ther. 2011 … and 9 other papers |
The historical description of endomyocardial disease began along two separate clinical paths. The first was in 1936, when the British physician Jack N. P. Davies, performing autopsies in Uganda on patients who had died of severe heart failure, first described a unique pathologic finding in which the endocardium was thickly fibrosed, centered on the apex, and ventricular filling was extremely restricted. Davies named this disease "tropical endomyocardial fibrosis (EMF)," and it was subsequently recognized as a common cause of restrictive cardiomyopathy in tropical and subtropical regions of Africa, Asia, and South America.
The second path was in 1936, when the Swiss physician Wilhelm Löffler described a unique endocarditis in two adult patients with hypereosinophilia, in which a thrombotic layer formed on the endocardium and eosinophilic infiltration was present. This later came to be called "Löffler endocarditis" or "eosinophilic endomyocardial disease." Löffler intuitively proposed that eosinophils were the mediators of cardiac injury, but the mechanism was unclear at the time.
In 1968, O. J. Andy and S. D. Neilson proposed a unifying hypothesis that Löffler endocarditis and tropical endomyocardial fibrosis may be different stages of the same disease. The concept is that the Löffler (eosinophilic) type is the active inflammation and thrombus-forming stage, and tropical endomyocardial fibrosis is the end-stage fibrotic stage after eosinophilic injury. This unifying view was subsequently widely accepted.
In the 1970s~80s, the association between hypereosinophilic syndrome (HES) and cardiac involvement was systematically studied. In the 1990s and 2000s, the discovery of the FIP1L1-PDGFRA fusion gene (2003, Cools et al.) enabled the innovative approach of tyrosine kinase inhibitor (imatinib) treatment in some HES patients. Since the 2000s, advances in cardiac MRI have made it possible to noninvasively distinguish the acute and fibrotic phases of Löffler endocarditis.
Endomyocardial disease is broadly divided into two subtypes, each with different causes. The main cause of eosinophilic endomyocardial disease (Löffler endocarditis) is cardiac involvement by hypereosinophilic syndrome (HES). HES is defined as a peripheral blood eosinophil count of 1,500/μL or more persisting for 6 months or longer, with end-organ involvement.
The causes of HES are diverse. Parasitic infections (filaria, Ascaris, Strongyloides, Toxocara, etc.) are the most common reactive causes. Mild eosinophilia occurs in allergic diseases (atopy, asthma, allergic rhinitis), but cardiac involvement is rare. In hematologic neoplastic HES, the causes include FIP1L1-PDGFRA (a fusion gene from an interstitial deletion on chromosome 4), ETV6-ABL1, and FGFR1 rearrangements. In addition, autoimmune diseases (eosinophilic granulomatosis with polyangiitis, formerly Churg-Strauss syndrome), drug hypersensitivity reactions, and graft-versus-host disease (GVHD) also cause eosinophil-related cardiac injury.
The causes of tropical endomyocardial fibrosis (tropical EMF) are multifactorial and not fully understood. The main hypotheses proposed are ① nutritional deficiency (magnesium and cerium deficiency, excessive intake of cyanogens, the toxin in cassava), ② repeated eosinophil activation due to parasitic and viral infections, ③ exposure to environmental toxins specific to low-income regions, and ④ genetic predisposition. Tropical EMF occurs endemically in equatorial Africa (especially Uganda, Nigeria, Mozambique), southern India, Sri Lanka, and parts of South America, while its frequency is uneven even within the same region, suggesting the combined action of environmental, nutritional, and genetic factors. Some studies have reported that serum cerium and magnesium are low in residents of tropical EMF regions and that EMF progression is suppressed with serum cerium supplementation, but a causal relationship has not been established.
Most endomyocardial disease is non-hereditary. However, genetic factors are involved in certain subtypes. The most important genetic abnormality in hematologic neoplastic HES is the FIP1L1-PDGFRA fusion gene, in which FIP1L1 and PDGFRA are fused by an interstitial deletion of about 800 kb on the long arm of chromosome 4 (4q12). This fusion gene produces a constitutively activated PDGFRA tyrosine kinase, causing abnormal clonal eosinophil proliferation. FIP1L1-PDGFRA-positive HES occurs mainly in men and responds dramatically to imatinib. In addition, FGFR1 (8p11) rearrangements, ETV6-ABL1, JAK2 variants, etc. are also causes of myeloid HES.
HLA-associated genetic predisposition to tropical endomyocardial fibrosis has been suggested in some studies. A study of a Mozambican patient cohort reported an association between specific HLA-DRB1 alleles and tropical EMF, but independent validation is needed. Familial occurrence has been reported sporadically, raising the possibility of genetic predisposition, but it is difficult to distinguish from shared environmental and dietary factors.
In Löffler endocarditis, the genetic association varies depending on the genetic background of the underlying HES. In autoimmune-based HES (e.g., eosinophilic granulomatosis with polyangiitis), genetic predisposition and environmental factors act in combination, and studies of ANCA-related gene polymorphisms are underway. Eosinophilia due to drug hypersensitivity reactions may be associated with HLA types (especially HLA-B*57:01 with abacavir, and HLA-B*15:02 with carbamazepine).
The epidemiology of endomyocardial disease differs greatly between the two subtypes. Tropical endomyocardial fibrosis (EMF) is the most common cause of restrictive cardiomyopathy in tropical and subtropical regions. About 12 million people are estimated to be affected worldwide, many of them concentrated in Africa (especially sub-Saharan). A population-based study in Mozambique produced the striking report that the prevalence of EMF reached about 20% of adults. It is also reported as a major heart disease in southern India (Kerala) and Sri Lanka.
Onset is common in children and adolescents, but onset in adulthood (20s~40s) is also common. The sex ratio varies by region but is generally similar or slightly higher in males. Prevalence is high in socioeconomically vulnerable groups, and because of low access to medical care, many patients are diagnosed only at the end stage. Eosinophilic endomyocardial disease (Löffler endocarditis) is rare worldwide, and there are no accurate prevalence statistics. The prevalence of the underlying HES is estimated at about 0.5~1 per 100,000 population, and cardiac involvement occurs in 40~50% of HES patients. FIP1L1-PDGFRA-positive HES is much more common in men (male:female = about 9:1). In East Asia, including Korea, both subtypes are extremely rare and are mainly diagnosed in immigrants and travelers with a history of residence in tropical regions.
The common core mechanism in the pathophysiology of endomyocardial disease is the cardiotoxic action of eosinophils. Eosinophils deposit in the endocardium and undergo degranulation, and the toxic proteins released cause myocardial injury.
Mechanism of eosinophil toxicity: Activated eosinophils release cytotoxic granules containing major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), and eosinophil peroxidase (EPO). These proteins cause myocardial injury and fibrosis through direct cytotoxicity to endocardial cells and cardiomyocytes, promotion of microthrombus formation, and stimulation of inflammatory cytokine secretion (IL-5, IL-13, TGF-β). In particular, MBP directly damages ion channels in the cardiomyocyte membrane and activates arachidonic acid metabolism, promoting platelet aggregation.
Three-stage progression of the disease: Endomyocardial disease progresses through three stages: acute necrotic phase → thrombotic phase → fibrotic phase. In the acute necrotic phase (weeks to months after onset), cardiomyocyte necrosis and eosinophilic infiltration are the main findings, and myocardial enzyme elevation appears together with fever and nonspecific symptoms. In the thrombotic phase, thrombi form on the damaged endocardium, increasing intraventricular filling impairment and the risk of thromboembolism. In the fibrotic phase, the thrombi are absorbed and the endocardium is replaced by thick fibrous tissue, fixing reduced ventricular volume and restrictive filling abnormalities. At this stage, cardiac injury is irreversible even if the eosinophilia resolves.
Outcome as restrictive cardiomyopathy: The fibrosed endocardium physically restricts ventricular relaxation, and the fibrothrombotic tissue filling the apex reduces the effective ventricular volume. Involvement of the tendinous valve apparatus of the atrioventricular valves (mitral, tricuspid) causes valvular regurgitation, worsening heart failure. Both ventricles may be involved simultaneously, and right ventricular involvement tends to be more common. Ascites, elevated jugular venous pressure, and hepatic congestion are the results of right heart failure.
The clinical symptoms of endomyocardial disease vary depending on the stage of disease (acute inflammatory phase vs chronic fibrotic phase) and the site of ventricular involvement (right ventricular predominant, left ventricular predominant, biventricular).
Symptoms of the acute phase (active phase of the eosinophilic subtype): Often appear together with systemic symptoms such as fever, general malaise, weight loss, and rash (urticaria, angioedema). Dyspnea, chest pain, and palpitations may be early signs of cardiac involvement. Blood tests show eosinophilia and elevated troponin. Because cardiac injury may be reversible if treated at this stage, early recognition is very important.
Symptoms of the chronic fibrotic phase: Biventricular filling restriction reduces cardiac output, and symptoms of congestive heart failure appear. Dyspnea (progressing from exertion → rest) and ascites are the most common main symptoms, and ascites is very prominent especially when right heart failure is marked. In the right ventricular predominant type, symptoms of right heart failure (lower limb edema, ascites, hepatomegaly, jaundice, early satiety) predominate. In the left ventricular predominant type, orthopnea, nocturnal dyspnea, and exercise intolerance due to pulmonary congestion are prominent.
Symptoms of thromboembolism: Thrombus formation on the endocardium causes systemic or pulmonary embolism. Cerebral infarction (hemiplegia, aphasia, visual field defects), lower limb arterial occlusion (sudden lower limb pain, coldness, pallor), pulmonary embolism (dyspnea, chest pain, hemoptysis), etc. may occur. Thromboembolism is one of the main causes of death in endomyocardial disease.
Symptoms of arrhythmia: Atrial fibrillation and atrial flutter are commonly present, worsening palpitations and exercise intolerance and increasing the risk of thromboembolism. Ventricular arrhythmias may also occur and can cause sudden death.
Symptoms of atrioventricular valve regurgitation: When fibrous tissue involves the chordae tendineae of the mitral or tricuspid valve, valvular regurgitation occurs. Tricuspid regurgitation is common and worsens symptoms of right heart failure. With mitral regurgitation, elevated pulmonary venous pressure and pulmonary congestion appear.
The physical signs of endomyocardial disease present as a combination of the typical pattern of restrictive cardiomyopathy, atrioventricular valve regurgitation, and findings of eosinophil-related multiorgan involvement.
Cardiovascular signs: Jugular venous pressure (JVP) is markedly elevated, and Kussmaul's sign (paradoxical rise in JVP on inspiration) may be observed. An S3 (third heart sound) may be heard, and a systolic murmur due to tricuspid regurgitation (increasing on inspiration, at the lower left sternal border) is characteristic. In the left ventricular predominant type, an apical systolic murmur due to mitral regurgitation appears. The heartbeat is regular or irregular due to atrial fibrillation.
Signs of systemic congestion: Hepatomegaly (tender hepatomegaly due to right heart congestion), ascites (massive ascites with severe right heart failure), pitting edema of the lower limbs, and pleural effusion (bilateral or right-predominant) appear. In end-stage patients, severe malnutrition, muscle wasting, and jaundice (cardiac cirrhosis) are also observed. Crackles may be heard on lung auscultation, but lung findings may be mild in the right-predominant type.
Laboratory findings: Peripheral blood eosinophilia (especially in the active phase of the eosinophilic subtype, > 1,500/μL). Elevated troponin I/T (acute phase), elevated BNP/NT-proBNP (reflecting heart failure severity). Thrombocytopenia, elevated ESR/CRP (active inflammatory phase). Elevated serum IgE (allergy-based HES). Increased eosinophil precursors on bone marrow examination; detection of the FIP1L1-PDGFRA fusion gene by FISH.
Echocardiographic findings: Characteristic findings are thickened endocardium (especially at the apex), apical obliterating thrombus, atrioventricular valve regurgitation (tricuspid, mitral), diastolic dysfunction (restrictive filling pattern: E/A ≫ 2, short deceleration time), reduced ventricular volume, and normal or mildly reduced left ventricular systolic function. In acute Löffler endocarditis, endocardial thickening appears as increased echogenicity, and apical thrombus is clearly visible.
Population-wide screening of the general population for endomyocardial disease is not performed. However, systematic early detection strategies are recommended in specific high-risk groups.
Cardiac screening in patients with hypereosinophilic syndrome (HES): Evaluation for cardiac involvement at diagnosis is essential in all patients with confirmed HES. Cardiac evaluation includes 12-lead ECG (nonspecific ST-T changes, atrial fibrillation), troponin (marker of myocardial injury), BNP/NT-proBNP (marker of heart failure), and echocardiography (endocardial thickening, thrombus, valvular regurgitation, diastolic dysfunction). When echocardiography shows abnormal or suspicious findings, cardiac MRI (including contrast enhancement) is performed to evaluate endocardial thickening, thrombus, and LGE (subendocardial fibrosis). Because cardiac involvement in HES patients may be present even at an early asymptomatic stage, cardiac involvement cannot be excluded by the absence of symptoms alone.
Patients with a history of residence in or travel to tropical regions: In patients with long-term residence in or travel to tropical regions of Africa, southern India, Sri Lanka, or South America who have unexplained heart failure, ascites, or atrioventricular valve regurgitation, tropical EMF must be actively considered in the differential diagnosis. Echocardiography is used as the primary screening tool, and the diagnostic criteria for tropical EMF (Mocumbi criteria) are applied.
High-risk groups for parasitic infection: When eosinophilia is identified in residents of or immigrants from areas with parasitic infections, troponin and echocardiography are recommended to check for cardiac involvement. In particular, when hypereosinophilia persists after filariasis, ascariasis, or strongyloidiasis infection, cardiac follow-up is needed.
The diagnosis of endomyocardial disease is made by integrating clinical history (eosinophilia or history of residence in tropical regions), cardiac imaging (echocardiography, cardiac MRI), endomyocardial biopsy, and laboratory tests.
Echocardiography: The most important primary diagnostic tool. The echocardiographic diagnostic criteria proposed by Mocumbi et al. are used as the standardized diagnostic method for tropical EMF. Major criteria: ① endocardial patches (echogenic patch) at ≥2 sites, ② intraventricular thrombus, ③ apical obliteration. Minor criteria: ① tricuspid/mitral regurgitation, ② endocardial thickening, ③ left/right atrial enlargement, ④ posterior pericardial effusion. Diagnosis is set as 1 or more major criteria or 2 or more minor criteria.
Cardiac MRI (CMR): With anatomic resolution superior to echocardiography, it evaluates endocardial thickening, apical thrombus, and involvement of the atrioventricular valve complex in detail. Late gadolinium enhancement (LGE) visualizes the distribution of subendocardial fibrosis, and apical subendocardial LGE is a characteristic pattern of endomyocardial disease. T2-weighted images identify endocardial edema and inflammation, which are prominent in the acute eosinophilic subtype. Cardiac MRI also helps select the involved site before endomyocardial biopsy.
Endomyocardial biopsy (EMB): Performed for histopathologic confirmation. In eosinophilic endomyocardial disease, eosinophilic infiltration, necrosis, and thrombi of the endocardium and myocardium are identified. In the fibrotic phase, dense collagen fibrosis is the main finding, and eosinophils are few or absent. Because false negatives can occur depending on the sampling site, targeted biopsy guided by cardiac MRI is recommended.
Tests for eosinophils and identification of the cause: Complete blood count with differential (CBC with differential), troponin, and BNP/NT-proBNP measurement. Parasite serology (filarial antibodies, stool examination for parasites), serum IgE, vitamin B12 (elevated in imatinib-responsive HES), bone marrow examination. Detection of the FIP1L1-PDGFRA fusion gene by FISH or RT-PCR. Search for hematologic neoplastic causes such as JAK2 variants and FGFR1 rearrangements.
Treatment of endomyocardial disease differs between the two subtypes, and acute-phase and chronic-phase treatments are distinguished.
Eosinophilic endomyocardial disease — immunosuppressive treatment: In the acute phase (active eosinophilia, myocardial involvement), corticosteroids are first-line treatment. Prednisolone is started at 1 mg/kg/day and tapered gradually, aiming to normalize the eosinophil count and halt progression of cardiac injury. In FIP1L1-PDGFRA-positive hematologic neoplastic HES, imatinib 100 mg/day as first-line treatment induces a dramatic reduction in eosinophils and improvement in cardiac function. For steroid refractoriness or relapse after tapering, hydroxyurea, interferon-α, mepolizumab (anti-IL-5 monoclonal antibody), etc. are considered.
Anticoagulation: Anticoagulation is given when endocardial thrombus is identified or when ventricular function is reduced. After heparin in the acute phase, maintenance anticoagulation is given with warfarin (INR 2~3) or a direct oral anticoagulant (DOAC). When atrial fibrillation is present, anticoagulation is essential for stroke prevention. When the thrombus is large or mobile (mobile thrombus), warfarin is preferred.
Heart failure treatment (symptom control): Ascites and pulmonary congestion are controlled with diuretics (furosemide, spironolactone). Beta-blockers and RAAS inhibitors are used as standard heart failure drugs but with caution in a restrictive filling pattern. In atrial fibrillation, rate control (digoxin, beta-blockers) is used, and amiodarone is used to maintain sinus rhythm.
Surgical treatment (tropical EMF and end-stage fibrotic phase): When symptoms are severe in the advanced fibrotic phase, surgical treatment combining endocardiectomy with atrioventricular valve repair or replacement is the only definitive treatment. Surgical mortality is about 10~15%, but after successful surgery, 5-year survival improves to 70~80%. Heart transplantation is also considered in end-stage heart failure.
The prognosis of endomyocardial disease differs greatly by stage at diagnosis and subtype. In the eosinophilic subtype, cardiac injury may be reversible if aggressive treatment is given in the acute necrotic phase, but the prognosis is poor when diagnosed in the fibrotic phase.
Eosinophilic endomyocardial disease: In FIP1L1-PDGFRA-positive patients, imatinib treatment rapidly normalizes eosinophils and induces improvement in cardiac function, greatly improving prognosis. After starting imatinib treatment, echocardiographic abnormalities improve or disappear in many patients. In steroid-responsive HES as well, progression can be halted when eosinophils are controlled with appropriate treatment. However, with treatment delay or relapse, irreversible fibrosis progresses.
Tropical endomyocardial fibrosis: It is difficult to halt the progression of fibrosis with medical treatment alone. The natural course in asymptomatic patients tends to be slow, but progression can be rapid after symptoms appear. When ascites is marked, 5-year survival with conservative treatment alone is reported to be about 40~50%. Functional status and survival improve meaningfully after surgical endocardiectomy, and 5-year survival after surgery at specialized centers reaches 70~80%. Thromboembolism and worsening heart failure are the main causes of death. The prognosis is very poor if left untreated or diagnosed at the end stage.
Follow-up: In eosinophilic endomyocardial disease, eosinophil count, troponin, BNP, and echocardiography are followed regularly. In patients treated with imatinib, the development of resistance (T674I, D816V variants) is monitored. In patients after surgery for tropical EMF, valve function, recurrence, and anticoagulation effect are evaluated regularly.
The approach to prevention of endomyocardial disease differs between the two subtypes. Complete primary prevention is difficult, but prevention of cardiac injury through early detection and control of the cause is possible.
Prevention of eosinophilic endomyocardial disease: Cardiac injury can be prevented or minimized by identifying and treating the cause of hypereosinophilic syndrome early. Starting imatinib early in FIP1L1-PDGFRA-positive HES patients can prevent cardiac involvement. In areas with parasitic infections, prophylactic anthelmintic administration (albendazole, ivermectin, etc.) and improved sanitation contribute to reducing causes of reactive eosinophilia. In eosinophilia due to drug hypersensitivity reactions, immediate discontinuation of the causative drug is essential.
Prevention of tropical EMF: There are study results suggesting that reducing exposure to cassava toxins in tropical regions (improved cassava processing methods), supplementing deficiencies of trace elements such as magnesium and cerium, and treating parasitic infections may contribute to reducing the risk of tropical EMF, but there is not yet an established prevention strategy. Nutrition improvement projects and parasite eradication programs are expected to affect the reduction of the tropical EMF burden in the long term.
Prevention of thromboembolism: In patients with identified endocardial thrombus, markedly reduced ventricular function, or accompanying atrial fibrillation, anticoagulation is a key measure to prevent thromboembolism (cerebral infarction, pulmonary embolism). Thrombus formation is monitored by regular echocardiographic follow-up.
Postoperative management: After surgical endocardiectomy, maintaining valve function, continuing immunosuppressive treatment to prevent recurrence (eosinophilic subtype), anticoagulation, and rehabilitation are important. Functional recovery is promoted by participation in a postoperative cardiac rehabilitation program.
Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH. A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med. 2008;359(1):43-49. DOI: 10.1056/NEJMoa0708321. PMID: 18596273.
Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201-1214. DOI: 10.1056/NEJMoa025217. PMID: 12660384.
Mankad R, Bonnichsen C, Mankad S. Hypereosinophilic syndrome: cardiac diagnosis and management. Heart. 2016;102(2):100-106. DOI: 10.1136/heartjnl-2015-307959. PMID: 26341565.
Salemi VMC, Rochitte CE, Shiozaki AA, et al. Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients. Circ Cardiovasc Imaging. 2011;4(3):304-311. DOI: 10.1161/CIRCIMAGING.110.957704. PMID: 21436277.
Bueno-Beti C, Mehta V, Bhatt DL, Seggewiss H. Endomyocardial fibrosis: a global review. Cardiovasc Drugs Ther. 2021;35(1):237-246. DOI: 10.1007/s10557-020-07014-5. PMID: 32594367.
Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):457-475. DOI: 10.1016/j.iac.2007.06.002. PMID: 17868859.
Grimaldi A, Mocumbi AO, Freers J, et al. Tropical endomyocardial fibrosis: natural history, challenges, and perspectives. Circulation. 2016;133(24):2503-2515. DOI: 10.1161/CIRCULATIONAHA.115.021178. PMID: 27297346.
Kleinfeldt T, Nienaber CA, Kische S, et al. Cardiac manifestation of the hypereosinophilic syndrome: new insights. Clin Res Cardiol. 2010;99(7):419-427. DOI: 10.1007/s00392-010-0140-z. PMID: 20213432.
Dantas EM, Salemi VMC, Wanderley MR Jr, et al. Surgical treatment of endomyocardial fibrosis. Braz J Cardiovasc Surg. 2019;34(3):348-358. DOI: 10.21470/1678-9741-2018-0432. PMID: 31291298.
Ginsberg F, Parrillo JE. Eosinophilic myocarditis. Heart Fail Clin. 2005;1(3):419-429. DOI: 10.1016/j.hfc.2005.06.004. PMID: 17386894.